AMPH

Amphastar Pharmaceuticals, Inc. (AMPH) | Rumor.io

Amphastar Pharmaceuticals

AMPH

Attention (50-day avg)0%

Attention rank (50-day avg)#2,971

Bullish sentiment (50-day avg)100%

Price to earnings ratio15.5

Market capitalization1.2B

Earnings per share1.77

Dividend yield (TTM)—

Revenue (annual)719.9M

Net income (annual)98.1M

Social

What share of all stock conversation is about AMPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Jun 5

The author is bullish on $AMPH and has taken a swing trade position on the 22.5 call expiring on June 18, with a purchase price of 0.45.
The author is confident in the pharma sector and believes $AMPH is a strong play, with a setup that looks solid and has high conviction.
The author is expecting a potential move in $AMPH, with some posts suggesting a high-confidence trade and others expressing a feeling of being "pretty confident" or "feeling good" about the trade.

Generated by AI

Sentiment

Of the messages about AMPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100%	93.53% +22.72
Bearish	—	0%	0%	6.47% -22.72

Jun 5

Amphastar Pharmaceuticals, Inc. (AMPH) is a promising pharma play with a strong setup.
The stock's price action is expected to be volatile, making it a suitable candidate for a swing trade.
Investors are showing high confidence in the company's prospects, with many taking positions on the stock's potential upside.

Generated by AI

Topics

Of the messages about AMPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	100%	24%
Announcements	—	—	0%	42.67%
Analysts	—	—	0%	20%
Controversies	—	—	0%	9.33%
Earnings	—	—	0%	4%
Macro	—	—	0%	0%

Earnings· Aug 8

Amphastar Pharmaceuticals, Inc. (AMPH) missed EPS estimates by $0.04 and reported FQ2 earnings of 3c EPS.
AMPH beat revenue estimates, reporting $71.04M in revenue for FQ2.
AMPH's stock dropped 9% since its last earnings report, with earnings expected to be reported on August 8 after close.

Analysts· Mar 13

Piper Jaffray Companies downgraded Amphastar Pharmaceuticals to Neutral with a price target of $23.
Needham & Company LLC downgraded Amphastar Pharmaceuticals to Hold.
Several analysts, including Needham & Company LLC and Piper Jaffray Companies, have downgraded Amphastar Pharmaceuticals in recent days.

Announcements· Aug 12

Amphastar Pharmaceuticals has secured an exclusive licensing agreement with Nanjing Anji Biotechnology to develop and commercialize three peptide products in the U.S. and Canada.
The agreement involves upfront payments totaling $6 million and potential milestone payments of up to $267 million for certain products.
Amphastar Pharmaceuticals has gained FDA approval for its iron sucrose injection, which is expected to boost market potential, and has also reported Q2 EPS beats at $0.85 despite a slight revenue drop.

Generated by AI

Community

Of the messages about AMPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	11.86%
Newcomers	100%	100%	100%	88.14%

Regulars· Jun 16

Amphastar Pharmaceuticals has been cut to a "buy" rating by a market analyst, suggesting increased potential for growth.
The company's stock has reached a new 52-week high, with a wide range bar and upper Bollinger band walk, indicating strong market momentum.
Amphastar Pharmaceuticals' EVP recently sold $241,200 worth of stock, which may be a strategic move or a sign of market sentiment.

Newcomers· Jun 5

New traders are focusing on Amphastar Pharmaceuticals' (AMPH) potential for a swing trade, with several mentioning buying calls at $0.45 for the June 18 expiration.
The newcomers are showing high confidence in AMPH's pharma play, with many expressing strong conviction in the stock's potential for a swing trade.
The traders are primarily interested in AMPH's June 18 call options, with all posts mentioning the same expiration date and strike price of $0.45, indicating a coordinated effort to take advantage of a potential opportunity.

Generated by AI

News

Amphastar CFO William Peters sells $103,475 in stock

6d agoInvesting.com

Amphastar Pharmaceuticals (NASDAQ:AMPH): Strongest Q2 Results from the Generic Pharmaceuticals Group

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q2 generic pharmaceuticals earnings season.

12d agoYahoo Finance

Amphastar at Wells Fargo conference: growth hinges on baqsimi, pipeline

21d agoInvesting.com

Amphastar Pharmaceuticals (AMPH) Rebounds In Focus, Is It Slightly Overvalued?

Recent Price Moves Put Amphastar Pharmaceuticals in Focus Amphastar Pharmaceuticals (AMPH) has drawn fresh attention after recent share price swings, with the stock closing at $23.18 and showing mixed performance over the past week, month, past 3 months, and year. Short term, Amphastar Pharmaceuticals has seen momentum build, with a 30-day share price return of 11.55% and a 90-day share price return of 19.55%. Yet the 1-year total shareholder return is down 21.21%, pointing to a recovery that...

23d agoYahoo Finance

Amphastar Pharmaceuticals (AMPH) Stock Looks Cheap With Earnings Doing The Heavy Lifting

Amphastar Pharmaceuticals stock presents a tricky mix for investors, with a steep 3 year share price decline set against valuation checks that now lean cheap on traditional multiples. Over the past 3 years the share price has fallen about 53.6%, which leaves current holders facing a deep drawdown and raises the question of whether the stock has been pushed too far down. Future expectations for Amphastar Pharmaceuticals around the durability of its product portfolio and its ability to convert...

25d agoYahoo Finance

Amphastar senior EVP Rong Zhou sells $75,305 in stock

26d agoInvesting.com

Also Discussed

Investors talking about AMPH also mention

#	Name	Attention
1	Invesco BuyBack Achievers ETFPKW	0%new
2	Interparfums, Inc.IPAR	0%new
3	Invesco BulletShares 2026 Corporate Bond ETFBSCQ	0%0
4	Huntington Bancshares Incorporated - Depositary Shares, Each Representing a 1/40th Interest in a Share of 6.875% Series J Non-Cumulative Perpetual Preferred StockHBANL	0%new
5	Solid Power, Inc. WarrantSLDPW	0%0
6	National HealthCare Properties Inc. 7.375% Perpetual Preferred StockNHPAP	0%0
7	Alkermes plcALKS	0%0
8	Lantheus Holdings Inc.LNTH	0%0
9	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
10	Amneal Pharmaceuticals, Inc.AMRX	0%+0

Amphastar Pharmaceuticals, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and markets technically challenging generic and proprietary injectable, inhalation, and intranasal products. Amphastar Pharmaceuticals, Inc. also supplies active pharmaceutical ingredient products, including insulin APIs, supporting both its own finished medicines and external customers. Its portfolio includes prescription and over-the-counter treatments used in hospital, urgent care, and retail pharmacy settings, with products addressing areas such as respiratory care, allergic reactions, anticoagulation, opioid overdose reversal, and diagnostic support. The company operates through its Pharmaceutical Products segment and emphasizes complex drug delivery systems, biologics, and biosimilar capabilities. Amphastar Pharmaceuticals, Inc. serves healthcare providers, distributors, and patients across the United States and selected international markets.

Website

Location

11570 6th Street

Rancho Cucamonga, CA, 91730

United States

Social

What share of all stock conversation is about AMPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Jun 5

The author is bullish on $AMPH and has taken a swing trade position on the 22.5 call expiring on June 18, with a purchase price of 0.45.
The author is confident in the pharma sector and believes $AMPH is a strong play, with a setup that looks solid and has high conviction.
The author is expecting a potential move in $AMPH, with some posts suggesting a high-confidence trade and others expressing a feeling of being "pretty confident" or "feeling good" about the trade.

Generated by AI

Sentiment

Of the messages about AMPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100%	93.53% +22.72
Bearish	—	0%	0%	6.47% -22.72

Jun 5

Amphastar Pharmaceuticals, Inc. (AMPH) is a promising pharma play with a strong setup.
The stock's price action is expected to be volatile, making it a suitable candidate for a swing trade.
Investors are showing high confidence in the company's prospects, with many taking positions on the stock's potential upside.

Generated by AI

Topics

Of the messages about AMPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	100%	24%
Announcements	—	—	0%	42.67%
Analysts	—	—	0%	20%
Controversies	—	—	0%	9.33%
Earnings	—	—	0%	4%
Macro	—	—	0%	0%

Earnings· Aug 8

Amphastar Pharmaceuticals, Inc. (AMPH) missed EPS estimates by $0.04 and reported FQ2 earnings of 3c EPS.
AMPH beat revenue estimates, reporting $71.04M in revenue for FQ2.
AMPH's stock dropped 9% since its last earnings report, with earnings expected to be reported on August 8 after close.

Analysts· Mar 13

Piper Jaffray Companies downgraded Amphastar Pharmaceuticals to Neutral with a price target of $23.
Needham & Company LLC downgraded Amphastar Pharmaceuticals to Hold.
Several analysts, including Needham & Company LLC and Piper Jaffray Companies, have downgraded Amphastar Pharmaceuticals in recent days.

Announcements· Aug 12

Amphastar Pharmaceuticals has secured an exclusive licensing agreement with Nanjing Anji Biotechnology to develop and commercialize three peptide products in the U.S. and Canada.
The agreement involves upfront payments totaling $6 million and potential milestone payments of up to $267 million for certain products.
Amphastar Pharmaceuticals has gained FDA approval for its iron sucrose injection, which is expected to boost market potential, and has also reported Q2 EPS beats at $0.85 despite a slight revenue drop.

Generated by AI

Community

Of the messages about AMPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	11.86%
Newcomers	100%	100%	100%	88.14%

Regulars· Jun 16

Amphastar Pharmaceuticals has been cut to a "buy" rating by a market analyst, suggesting increased potential for growth.
The company's stock has reached a new 52-week high, with a wide range bar and upper Bollinger band walk, indicating strong market momentum.
Amphastar Pharmaceuticals' EVP recently sold $241,200 worth of stock, which may be a strategic move or a sign of market sentiment.

Newcomers· Jun 5

New traders are focusing on Amphastar Pharmaceuticals' (AMPH) potential for a swing trade, with several mentioning buying calls at $0.45 for the June 18 expiration.
The newcomers are showing high confidence in AMPH's pharma play, with many expressing strong conviction in the stock's potential for a swing trade.
The traders are primarily interested in AMPH's June 18 call options, with all posts mentioning the same expiration date and strike price of $0.45, indicating a coordinated effort to take advantage of a potential opportunity.

Generated by AI

Amphastar Pharmaceuticals

Social

Jun 5

Jun 5

Earnings· Aug 8

Analysts· Mar 13

Announcements· Aug 12

Regulars· Jun 16

Newcomers· Jun 5

Amphastar CFO William Peters sells $103,475 in stock

Amphastar Pharmaceuticals (NASDAQ:AMPH): Strongest Q2 Results from the Generic Pharmaceuticals Group

Amphastar at Wells Fargo conference: growth hinges on baqsimi, pipeline

Amphastar Pharmaceuticals (AMPH) Rebounds In Focus, Is It Slightly Overvalued?

Amphastar Pharmaceuticals (AMPH) Stock Looks Cheap With Earnings Doing The Heavy Lifting

Amphastar senior EVP Rong Zhou sells $75,305 in stock

Also Discussed

Amphastar Pharmaceuticals, Inc.

Company Information

Location

Amphastar CFO William Peters sells $103,475 in stock

Amphastar Pharmaceuticals (NASDAQ:AMPH): Strongest Q2 Results from the Generic Pharmaceuticals Group

Amphastar at Wells Fargo conference: growth hinges on baqsimi, pipeline

Amphastar Pharmaceuticals (AMPH) Rebounds In Focus, Is It Slightly Overvalued?

Amphastar Pharmaceuticals (AMPH) Stock Looks Cheap With Earnings Doing The Heavy Lifting

Amphastar senior EVP Rong Zhou sells $75,305 in stock

Also Discussed

Social

Jun 5

Jun 5

Earnings· Aug 8

Analysts· Mar 13

Announcements· Aug 12

Regulars· Jun 16

Newcomers· Jun 5